Other evidence has demonstrated that pharmacological AMPK activation attenuates the development of cardiac hypertrophy by inhibiting protein synthesis through the inactivation of the mammalian target of rapamycin (mTOR) signaling pathway (Chan et al., 2004, 2008; Kang et al., 2011). The gene discussed is MTOR; the disease is cardiac hypertrophy.